Brief: Savara Completes Enrollment Of Phase 3 Impala-2 Trial Of Molgramostim Nebulizer Solution

Savara

26/06/2023 13:38

June 26 (Reuters) - Savara Inc  SVRA.O :
    * SAVARA COMPLETES ENROLLMENT OF PIVOTAL PHASE 3 IMPALA-2
TRIAL OF
MOLGRAMOSTIM NEBULIZER SOLUTION (MOLGRAMOSTIM) IN AUTOIMMUNE
PULMONARY ALVEOLAR PROTEINOSIS (APAP)
    * SAVARA INC: REMAINS ON-TRACK TO REPORT TOP LINE DATA BY
END OF
2Q 2024

Source text for Eikon:  ID:nBw8Rmjy2a 
Further company coverage:  SVRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))